edoc

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma : a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)

Koeberle, Dieter and Montemurro, Michael and Samaras, Panagiotis and Majno, Pietro and Simcock, Mathew and Limacher, Andreas and Lerch, Stefanie and Kovàcs, Katalin and Inauen, Roman and Hess, Vivianne and Saletti, Piercarlo and Borner, Markus and Roth, Arnaud and Bodoky, György. (2010) Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma : a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). The oncologist, Vol. 15. pp. 285-292.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004473

Downloads: Statistics Overview

Abstract

Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC).
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Onkologie (Herrmann)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Onkologie (Herrmann)
UniBasel Contributors:Hess, Viviane
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:AlphaMed Press
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:44

Repository Staff Only: item control page